News at Tekton

Stay informed about Tekton Research's latest developments, achievements, and contributions to clinical research.

St. Louis Team Exceeds Enrollment Goal in Alzheimer’s Trial

Celebrating a job well done by Ernest Graypel, MD, MHA, Brandon Lenfest, Mejra Dzinic, and our St. Louis team! After joining an Alzheimer’s trial as a rescue site, the team exceeded its enrollment goal. Thank you for the hard work behind this accomplishment!

Tekton Adds Executive Leadership Across Key Therapeutic Areas and Patient Engagement

Tekton Research, a multi-specialty clinical research site organization, has hired three vice presidents to lead its neuroscience, cardiometabolic, and endocrinology research operations, and to advance its patient engagement strategy. All three began their careers working inside research sites. Patricia Brown, PhD, APRN, joins as Vice President, Clinical Operations, Neuroscience. Brown … Read more

Introducing the Tekton Psychiatry Team

Tekton has introduced the Tekton Psychiatry Team, bringing together physician-investigators and operational leaders to provide centralized expertise for mental and behavioral health studies across 17 Tekton sites. From protocol review and rater consistency to participant engagement and staff mentorship, the team strengthens how Tekton sites support mood, anxiety, addiction, and behavioral … Read more

Tekton Sites Achieve 300% of Combined Obesity Trial Enrollment Goal

Tekton Research’s San Antonio, TX, and Edmond, OK, teams achieved 300% of their combined initial enrollment goal for a recent Phase 2 obesity trial, randomizing 60 participants against a target of 20. Congratulations to: Jara McDonald, MD, FAAFP, DABOM, CPI, Evelyn Guajardo, and our San Antonio team Kyle Rickner, MD, … Read more

Marlee Sanchez Named a Finalist for the First-Ever SCRS Next Up Award

Tekton Research is proud to congratulate Marlee Sanchez, Clinical Research Coordinator III in Fort Collins, CO, on being named a finalist for the first-ever SCRS Next Up Award. Marlee brings care and a collaborative spirit to her work, guiding participants through complex studies, mentoring colleagues, and helping Tekton’s sites across … Read more

From the Navy, to the Operating Room, to IP Management: A Conversation With Brian Bailey

Brian Bailey, MSBS-MS, is Tekton’s Clinical Compliance and Operations Director, based in Austin, Texas. He oversees site-level investigational product (IP) management and helps set compliance and operations processes companywide. We spoke with him about his Navy and surgical background, improving temperature-alert response across Tekton, and what Sponsors and CROs can … Read more

Tekton Expands to Houston, Opens Site With Psychiatrist Lawrence Ginsberg, MD

Tekton is expanding to Houston, TX, with the addition of Lawrence D. Ginsberg, MD. Dr. Ginsberg will lead adult and pediatric psychiatry studies as a Principal Investigator from his clinic, Red Oak Psychiatry Associates. This marks Tekton’s first research location in Houston. Dr. Ginsberg has practiced psychiatry since 1985 and … Read more

Tekton Welcomes Psychiatrist Andrew H. Martin, MD, to San Antonio Investigator Team

Andrew H. Martin, MD, psychiatrist and founder of Texas Family Psychiatry, will expand Tekton’s psychiatry research capabilities in San Antonio. Tekton is pleased to welcome Andrew H. Martin, MD, as a Principal Investigator at its San Antonio dedicated research center. Dr. Martin is a psychiatrist with more than 20 years … Read more

Austin Site Screens First Participant Globally for Boehringer Ingelheim Systemic Sclerosis Study

Tekton’s Austin, TX, team screened the first participant globally for Boehringer Ingelheim’s Phase 3 study evaluating nerandomilast for systemic sclerosis. Congratulations to Paul Pickrell, MD, and our entire Austin team on this milestone!

Pablo Mora, MD, Authors Two Articles in The Lancet on Zenagamtide

Pablo Mora, MD, is the lead author of two new articles published in The Lancet. The articles report Phase 2 results for zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist being studied in adults with type 2 diabetes. Across cohorts, both once-weekly subcutaneous and once-daily oral formulations produced substantial … Read more

Subscribe to Inside Tekton on LinkedIn

Get Tekton's monthly newsletter that rounds up the latest from Tekton, and the clinical research landscape.